Neuland Laboratories: An Analyst’s View
Nuvama Institutional Equities has kept its “BUY” rating on Neuland Laboratories, setting a target price of ₹22,130. This recommendation is based on estimates of future profits. They arrived at this rating after seeing strong interest from investors at a recent event where Neuland discussed its plans for growing its business.
Key Points
- Nuvama recommends “BUY” with a target of ₹22,130.
- Neuland’s growth is driven by peptide manufacturing expansion.
- Expected revenue growth: 24% CAGR (FY25-28E).
- Profit after tax growth: 49% CAGR (FY25-28E).
- Margin targets: EBITDA 25-30% over the medium term.
- New peptide facility investment: ₹250 crore anticipated.
Neuland Laboratories is specializing in making specific types of medicines, especially those using peptides. They’re building a larger factory to make these medicines. This expansion is expected to significantly increase their ability to produce these specialized ingredients.
The company believes that global demand for peptides – used in medicines to treat diabetes and other conditions – will increase. They think they’re well-positioned to take advantage of this growing demand. They anticipate that this will help them grow their business significantly.
Neuland’s plans include investing in research and development. This new R&D center will allow them to explore and develop new medicines. The expansion will significantly increase the company’s ability to research and innovate.
They’ve already expanded their factory to make more medicine. This expansion gives them room to grow and supports their plans to work on 16 different medicine projects that are currently being tested.
Management is confident that Neuland can maintain its profit margins. The company is focusing on making complex medicines to ensure long-term growth and profitability.
“Neuland Laboratories is strategically positioned for sustainable growth through focused API development.”
